Quetiapine augmentation in severe Obsessive Compulsive Disorder

Study identifier:5077/9059

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Quetiapine augmentation in severe Obsessive Compulsive Disorder (OCD) – Pilot Study

Medical condition

Obsessive Compulsive Disorder

Phase

Phase 3

Healthy volunteers

Study drug

quetiapine fumarate, SSRI/Clomipramine

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 Apr 2002

Primary Completion Date: -

Study Completion Date: 01 Mar 2006

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2007 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Lübeck, Germany

Location

Research Site

Freiburg, Germany

Arms	Assigned Interventions

"There is no result for the study"

Documents available

Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information

+49 (0)4103/708-0

Investigators

Principal Investigator

AstraZeneca Germany Medical Director

AstraZeneca

Quetiapine augmentation in severe Obsessive Compulsive Disorder

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Research Site

Research Site

Documents available

Trial Results Summaries

Contacts

Contact

Investigators

Principal Investigator